Physician profile
Brian D Vicuna
NPI 1275755670
$107,371.44
in general payments reported to CMS, 2019-2025
95 companies · $15K in 2025
The $15K reported for 2025 was more than what 85% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,601 · 2020: $12K · 2021: $22K · 2022: $24K · 2023: $9,439 · 2024: $21K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,070 · Travel and Lodging: $1,859 · Honoraria: $1,300 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,167.13 |
| Food and Beverage | $10,513.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,070.00 |
| Travel and Lodging | $1,859.44 |
| Honoraria | $1,300.00 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $377.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $15,914.85 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Abbvie INC. | $15,273.22 | 2021-2025 | Venclexta, Lupron Depot |
| Janssen Scientific Affairs, LLC | $6,551.41 | 2021-2025 | Rybrevant, Tecvayli, Talvey |
| Kite Pharma, INC. | $5,624.02 | 2022-2023 | Yescarta |
| Pfizer INC. | $4,842.22 | 2019-2025 | |
| Gilead Sciences, INC. | $4,702.83 | 2021-2025 | Trodelvy |
| Taiho Oncology, INC. | $4,307.04 | 2021-2024 | |
| Incyte Corporation | $4,151.60 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $4,070.46 | 2019-2025 | |
| Celgene Corporation | $4,054.58 | 2019-2025 | Reblozyl, Opdualag |
| Ipsen Biopharmaceuticals, INC | $3,540.70 | 2020-2025 | Tazverik, Onivyde, Somatuline Depot |
| Bayer Healthcare Pharmaceuticals INC. | $3,379.59 | 2019-2025 | |
| Blueprint Medicines Corporation | $3,303.23 | 2020-2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $2,313.42 | 2023-2025 | Fruzaqla, Alunbrig, Iclusig |
| Lilly USA, LLC | $2,287.87 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
Show all 91 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $2,222.10 | 2021-2025 | |
| Janssen Biotech, INC. | $2,195.95 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Eisai INC. | $1,901.86 | 2021-2025 | |
| Daiichi Sankyo INC. | $1,686.02 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Exelixis INC. | $1,460.89 | 2019-2025 | Cabometyx |
| Array Biopharma INC | $1,352.74 | 2021-2025 | Lorbrena, Braftovi, Mektovi |
| Amgen INC. | $1,091.47 | 2019-2023 | Blincyto, Nplate, Lumakras |
| Aadi Bioscience, INC. | $1,017.97 | 2023-2025 | Fyarro |
| Beigene USA, INC. | $823.18 | 2020-2024 | Brukinsa |
| Astellas Pharma US INC | $726.75 | 2019-2025 | Xospata, Xtandi, Padcev |
| Genentech USA, INC. | $571.77 | 2019-2025 | Tecentriq, Phesgo, Perjeta |
| Beigene, Ltd. | $525.00 | 2021 | |
| Sobi, INC | $435.16 | 2022-2025 | |
| Genzyme Corporation | $422.67 | 2019-2025 | |
| Seagen INC. | $402.89 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Sanofi-Aventis U.S. LLC | $349.83 | 2019-2022 | |
| Emd Serono, INC. | $324.62 | 2019-2025 | Bavencio |
| Jazz Pharmaceuticals INC. | $307.17 | 2020-2024 | |
| Glaxosmithkline, LLC. | $306.18 | 2020-2025 | Zejula, Ojjaara |
| Chiesi USA, INC. | $300.00 | 2025 | Ferriprox |
| Aveo Pharmaceuticals, INC. | $285.89 | 2022-2025 | Fotivda |
| Alexion Pharmaceuticals, INC. | $279.31 | 2020-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $278.62 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Tempus Ai, INC | $276.98 | 2024-2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $260.91 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $222.54 | 2021-2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $213.94 | 2019-2023 | Imbruvica, Epkinly |
| Dendreon Pharmaceuticals LLC | $201.19 | 2020-2025 | Provenge |
| Stemline Therapeutics INC. | $177.90 | 2023-2024 | Orserdu |
| Sumitomo Pharma America, INC. | $164.50 | 2023-2025 | Orgovyx |
| Agios Pharmaceuticals, INC. | $153.68 | 2020-2025 | Pyrukynd |
| Sirtex Medical INC | $145.70 | 2025 | Sir-Spheres Microspheres |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.01 | 2021-2025 | Gilotrif |
| Genentech, INC. | $127.98 | 2021-2025 | Itovebi, Alecensa, Tecentriq Hybreza |
| Mirati Therapeutics, INC. | $109.43 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $101.92 | 2023-2025 | Libtayo |
| Genmab U.S., INC. | $97.74 | 2024-2025 | Epkinly, Tivdak |
| Global Blood Therapeutics, INC. | $82.55 | 2020-2022 | |
| Intuitive Surgical, INC. | $82.04 | 2024 | |
| Rigel Pharmaceuticals, INC. | $77.37 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $62.63 | 2020-2022 | |
| Dova Pharmaceuticals | $56.51 | 2020-2021 | |
| Blue Earth Diagnostics | $56.38 | 2020 | |
| Novocure INC. | $56.15 | 2021-2022 | |
| Heron Therapeutics, INC. | $49.97 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $48.31 | 2023-2025 | Clonoseq |
| Clovis Oncology, INC. | $47.00 | 2019-2021 | |
| Kyowa Kirin, INC. | $42.19 | 2021 | |
| Alnylam Pharmaceuticals INC. | $42.18 | 2025 | Amvuttra, Givlaari |
| Accord Healthcare, INC. | $38.36 | 2023 | |
| Angiodynamics, INC. | $37.45 | 2021 | |
| Cti Biopharma Corp. | $34.66 | 2023 | Vonjo |
| Deciphera Pharmaceuticals INC. | $33.80 | 2020 | |
| Springworks Therapeutics, INC. | $33.21 | 2024-2025 | Ogsiveo |
| Tesaro, INC. | $32.30 | 2019 | |
| Tersera Therapeutics LLC | $30.99 | 2024 | Xermelo |
| Syndax Pharmaceuticals, INC. | $30.70 | 2025 | |
| Pharmaessentia USA Corporation | $29.81 | 2023 | Besremi |
| Legend Biotech USA INC. | $29.76 | 2025 | Carvykti |
| Macrogenics, INC. | $29.11 | 2022 | |
| Astellas Pharma Global Development | $28.74 | 2019-2024 | Xospata |
| Epizyme, INC. | $26.71 | 2022 | |
| Sun Pharmaceutical Industries INC. | $25.63 | 2025 | |
| Verity Pharmaceuticals INC. | $23.84 | 2025 | Trelstar |
| X4 Pharmaceuticals, INC. | $23.57 | 2025 | Xolremdi |
| Foundation Medicine, INC. | $23.25 | 2020 | |
| Morphosys, US INC. | $22.65 | 2021 | |
| Bio Products Laboratory USA, INC. | $22.03 | 2019 | |
| Emmaus Medical, INC. | $21.04 | 2023 | Endari |
| Myovant Sciences INC. | $20.83 | 2022 | |
| G1 Therapeutics, INC. | $18.77 | 2022 | |
| Apellis Pharmaceuticals, INC. | $18.44 | 2022 | |
| Ge Healthcare | $17.36 | 2022 | |
| Shire North American Group INC | $16.35 | 2019 | |
| Beone Medicines USA, INC. | $15.21 | 2025 | Tevimbra |
| Janssen Pharmaceuticals, INC | $14.09 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,006.09 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Vicuna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.